Source link : https://www.newshealth.biz/health-news/177lu-dotatate-shows-promise-for-refractory-meningioma/
WASHINGTON — A phase 2 study has demonstrated encouraging results for lutetium-177 (177Lu) dotatate in patients with surgery- and radiation-refractory meningioma. Kenneth Merrell, MD, MS, presented the findings, which, he said, “offer new hope for patients with limited treatment options,” at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. Study Rationale Kenneth Merrell, […]
Author : News Health
Publish date : 2024-10-03 13:53:44
Copyright for syndicated content belongs to the linked Source.